Alere’s PoC HIV Test Prequalified by WHO

The rapid fourth-generation test is now available for public sector procurement in countries where resources are limited.

HIV Combo / Photo: Alere
HIV Combo / Photo: Alere

A PharmaBiz.com article dated July 16th discussed the recent World Health Organization prequalification awarded to Alere for their HIV Combo, a fourth-generation point-of-care test. Second- and third-generation tests only detect antibodies against HIV, which can take up to 3 weeks to appear after infection has occurred. This new test detects both HIV-1/2 antibodies and the HIV-1 p24 antigen, which can appear up to 7.7 days earlier, which increases case findings at a time when individuals are 10x more likely to transmit HIV. According to the article, the Alere HIV Combo is not approved for sale in the US, but Alere Determine HIV-1/2 Ag/Ab Combo is CLIA-waived and available in the US.

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO